ARTICLE | Company News
Ionis, AstraZeneca in antisense kidney disease deal
February 20, 2018 9:48 PM UTC
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) worldwide rights to develop and commercialize antisense candidate IONIS-AZ5-2.5Rx (AZD2373), which is in development to treat an undisclosed genetically associated form of kidney disease. Ionis will receive $30 million up front and is eligible for up to $300 million in developmental and regulatory milestones, plus tiered double-digit royalties.
In 2015, the partners expanded their antisense deal to include undisclosed targets for cardiovascular, metabolic and renal diseases. The pharma has an option to license a compound against each target under the deal (see BioCentury Extra, Aug. 3, 2015)...